INSTAGE (TM) : A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministrated with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Nintedanib (Primary) ; Sildenafil
- Indications Idiopathic pulmonary fibrosis; Lung disorders
- Focus Therapeutic Use
- Acronyms INSTAGE; INSTAGE (TM)
- Sponsors Boehringer Ingelheim
- 20 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Nov 2017 Planned End Date changed from 15 Mar 2018 to 19 Apr 2018.
- 17 Oct 2017 Planned End Date changed from 14 May 2018 to 15 Mar 2018.